Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Soheila Rezaei, Ali Taheri, Saeed Taheri, Sara Kasirzadeh, Behzad Fatemi & Mende M Sorato. (2022) Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology 15:6, pages 767-777.
Read now
Read now
Nicole M Gerlanc, Jennifer Cai, Joseph Tkacz, Susan C Bolge & Brenna L Brady. (2017) The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin. Diabetes, Metabolic Syndrome and Obesity 10, pages 89-99.
Read now
Read now
Shana B Traina, Susan D Mathias, Hilary H Colwell, Ross D Crosby & Charles Abraham. (2016) The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents. Patient Preference and Adherence 10, pages 213-222.
Read now
Read now
Markus F Scheerer, Roland Rist, Orm Proske, Annika Meng & Karel Kostev. (2016) Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes, Metabolic Syndrome and Obesity 9, pages 337-345.
Read now
Read now
Lia Alves-Cabratosa, Maria García-Gil, Marc Comas-Cufí, Ruth Martí, Anna Ponjoan, Dídac Parramon, Jordi Blanch & Rafel Ramos. (2016) Diabetes and new-onset atrial fibrillation in a hypertensive population. Annals of Medicine 48:3, pages 119-127.
Read now
Read now
Shana B Traina, Hilary H Colwell, Ross D Crosby & Susan D Mathias. (2015) Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire. Patient Related Outcome Measures 6, pages 103-115.
Read now
Read now
Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu & Hengjin Dong. (2015) Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. Journal of Medical Economics 18:10, pages 808-820.
Read now
Read now
Robert M. Guthrie. (2015) Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine 127:5, pages 463-479.
Read now
Read now
Shana Traina, Robert Guthrie & April Slee. (2014) The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes. Postgraduate Medicine 126:3, pages 7-15.
Read now
Read now
Simon Condliffe & Charles R. Link. (2014) Racial differences in the effects of hypertension and obesity on health expenditures by diabetes patients in the US. Applied Economics Letters 21:4, pages 280-283.
Read now
Read now
Simon Condliffe, CharlesR. Link, Shreekant Parasuraman & MichaelF. Pollack. (2013) The effects of hypertension and obesity on total health-care expenditures of diabetes patients in the United States. Applied Economics Letters 20:7, pages 649-652.
Read now
Read now
Priscilla A Hollander. (2012) Insulin detemir for the treatment of obese patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 5, pages 11-19.
Read now
Read now
Devesh Sennik, Fahad Ahmed & David Russell-Jones. (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 7:1, pages 15-26.
Read now
Read now
Scott E Nelson. (2011) Detemir as a once-daily basal insulin in type 2 diabetes. Clinical Pharmacology: Advances and Applications 3, pages 27-37.
Read now
Read now
Articles from other publishers (52)
David Seung U. Lee & Howard Lee. (2022) Adherence and persistence rates of major antidiabetic medications: a review. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Yue Dong, Zhenyuan Chen, Yanhong Gong, Yanping Han, Hanbing Yu, Xiaozhou Zeng, Zimei Chen, Rongrong An, Na Sun & Xiaoxv Yin. (2022) The Risks of Cardiovascular Disease Following Weight Change in Adults With Diabetes: A Cohort Study and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism 107:10, pages e4177-e4186.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Supratik Bhattacharyya, Aditya Bikram Mishra & Maneesha Khalse. (2021) CLINICAL EFFECTIVENESS OF FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN (EMPA/LINA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNWILLING TO CONTINUE BASAL INSULIN THERAPY: A REAL-WORLD EXPERIENCE IN INDIAN SETTING. INDIAN JOURNAL OF APPLIED RESEARCH, pages 42-44.
Crossref
Crossref
Rory J. McCrimmon, Andrei-Mircea Catarig, Juan P. Frias, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke & Ildiko Lingvay. (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63:3, pages 473-485.
Crossref
Crossref
Sheyda Sofizadeh, Henrik Imberg, Arndís F. Ólafsdóttir, Magnus Ekelund, Sofia Dahlqvist, Irl Hirsch, Karin Filipsson, Bo Ahrén, Stefan Sjöberg, Jaako Tuomilehto & Marcus Lind. (2019) Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. Diabetes Therapy 10:6, pages 2115-2130.
Crossref
Crossref
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge Jabbour & Marcus Lind. (2019) Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care 42:8, pages 1464-1472.
Crossref
Crossref
Włodzimierz Mrówczyński. (2019) Health Benefits of Endurance Training: Implications of the Brain-Derived Neurotrophic Factor—A Systematic Review. Neural Plasticity 2019, pages 1-15.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Xuejing Li, Suhui Qie, Xianying Wang, Yingying Zheng, Yang Liu & Guoqiang Liu. (2018) The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Endocrine 62:3, pages 535-545.
Crossref
Crossref
Andrew J. Ahmann, Matthew CapehornGuillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam P. Annett & Vanita R. Aroda. (2018) Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care 41:2, pages 258-266.
Crossref
Crossref
Shana B. Traina, April Slee, Suzy Van Sanden & Joris Diels. (2017) An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin. Diabetes Therapy 9:1, pages 125-140.
Crossref
Crossref
Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty & David D. Dore. (2017) Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism 19:10, pages 1425-1435.
Crossref
Crossref
Franck Boccara, Ricardo Dent, Luis Ruilope & Paul Valensi. (2017) Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Advances in Therapy 34:8, pages 1876-1896.
Crossref
Crossref
Zixuan Wang, Lin Hou, Lanhui Huang, Jun Guo & Xinli Zhou. (2017) Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice. Biochemical and Biophysical Research Communications 486:1, pages 116-123.
Crossref
Crossref
Christopher Sorli, Shin-ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen & Stephen C Bain. (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology 5:4, pages 251-260.
Crossref
Crossref
Nina A. Petunina, Anna L. Terekhova & Ekaterina V. Goncharova. (2016) Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes mellitus 19:6, pages 511-517.
Crossref
Crossref
Charmi A. Patel, Robert A. Bailey, Ujjwala Vijapurkar, Gary Meininger & Lawrence Blonde. (2016) A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research 16:1.
Crossref
Crossref
Janice M. S. Lopez, Bozena J. Katic, Marcy Fitz-Randolph, Richard A. Jackson, Wing Chow & C. Daniel Mullins. (2016) Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu & Hengjin Dong. (2016) Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0167190.
Crossref
Crossref
Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen & Hengjin Dong. (2016) Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0165629.
Crossref
Crossref
Gabriel Cuatrecasas & Fernando Goñi-Goicoechea. (2016) Perfil clínico de los pacientes con diabetes mellitus tipo 2 tratados con inhibidores del cotransportador sodio-glucosa tipo 2 y experiencia clínica real en España. Medicina Clínica 147, pages 30-34.
Crossref
Crossref
Anne E. de Leeuw & Rudolf A. de Boer. (2016) Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. European Heart Journal - Cardiovascular Pharmacotherapy 2:4, pages 244-255.
Crossref
Crossref
Erin K. Buysman, Wing Chow, Henry J. Henk & Marcia F. T. Rupnow. (2015) Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Marcus Lind, Irl B. Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Ole Torffvit & Nils-Gunnar Pehrsson. (2015) Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes 9:1, pages 15-22.
Crossref
Crossref
Ugne Sabale, Mattias Ekman, Ola Granström, Klas Bergenheim & Phil McEwan. (2015) Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary Care Diabetes 9:1, pages 39-47.
Crossref
Crossref
Nick Finer. (2014) Comment on Balkau et al. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care 2014;37:2108–2113. Diabetes Care 37:12, pages e265-e265.
Crossref
Crossref
Michelle Orme, Peter Fenici, Isabelle Duprat Lomon, Gail Wygant, Rebecca Townsend & Marina Roudaut. (2014) A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetology & Metabolic Syndrome 6:1.
Crossref
Crossref
Henrik H. Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein & Eric Mayoux. (2014)
The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves
β
-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
. Journal of Pharmacology and Experimental Therapeutics 350:3, pages 657-664.
Crossref
Crossref
S. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood & A. H. Barnett. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 433-442.
Crossref
Crossref
Carrie McAdam-Marx, Jayanti Mukherjee, Brandon K. Bellows, Sudhir Unni, Xiangyang Ye, Uchenna Iloeje & Diana I. Brixner. (2014) Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Research and Clinical Practice 103:3, pages 402-411.
Crossref
Crossref
J. P. H. Wilding, V. Woo, K. Rohwedder, J. Sugg & S. Parikh. (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes, Obesity and Metabolism 16:2, pages 124-136.
Crossref
Crossref
S. Macha, P. Rose, M. Mattheus, R. Cinca, S. Pinnetti, U. C. Broedl & H. J. Woerle. (2014) Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes, Obesity and Metabolism 16:2, pages 118-123.
Crossref
Crossref
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J. Woerle & Klaus Dugi. (2013) Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology in Drug Development 2:2, pages 152-161.
Crossref
Crossref
Chieh-Hsiang Lu, Ta-Jen Wu, Kuang-Chung Shih, Ewan Ni, Victoria Reed, Maria Yu, Wayne H.-H. Sheu & Lee-Ming Chuang. (2013) Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. Journal of the Formosan Medical Association 112:3, pages 144-150.
Crossref
Crossref
Kay Craven, Susan Bane & Kathryn M. Kolasa. (2013) The Dance. Nutrition Today 48:1, pages 19-25.
Crossref
Crossref
A. H. Barnett, S. Patel, R. Harper, R. Toorawa, S. Thiemann, M. von Eynatten & H.‐J. Woerle. (2012)
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase
III
trial with a 34‐week active‐controlled extension
. Diabetes, Obesity and Metabolism 14:12, pages 1145-1154.
Crossref
Crossref
M. Davies & J. Speight. (2012) Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 14:10, pages 882-892.
Crossref
Crossref
Marcus Lind. (2012) Incretin therapy and its effect on body weight in patients with diabetes. Primary Care Diabetes 6:3, pages 187-191.
Crossref
Crossref
H.W. Esther Chan, B. Ashan, P. Jayasekera, Andrew Collier & Sujoy Ghosh. (2012) A new class of drug for the management of type 2 diabetes: Sodium glucose co-transporter inhibitors: ‘Glucuretics’. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 6:4, pages 224-228.
Crossref
Crossref
Celine Foote, Vlado Perkovic & Bruce Neal. (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research 9:2, pages 117-123.
Crossref
Crossref
Tom Bartol. (2012) Improving the treatment experience for patients with type 2 diabetes: Role of the nurse practitioner. Journal of the American Academy of Nurse Practitioners 24, pages 270-276.
Crossref
Crossref
David Benaiges Boix, Albert Goday Arno & Juan Pedro-Botet. (2012) La cirugía bariátrica como tratamiento de la diabetes tipo 2. Medicina Clínica 138:9, pages 391-396.
Crossref
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Crossref
Adriaan Kooy. (2015) Hypoglycemie bij diabetes: relevant voor het cardiovasculaire risico en de cognitie?. Nederlands Tijdschrift voor Diabetologie 9:2, pages 52-61.
Crossref
Crossref
Sylvie Dejager & Anja Schweizer. (2011) Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Therapy 2:2, pages 51-66.
Crossref
Crossref
Clifford J. Bailey. (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends in Pharmacological Sciences 32:2, pages 63-71.
Crossref
Crossref
Cristina Comi-Diaz, José M. Miralles-García, Lucio Cabrerizo, María Pérez, Xavier Masramon & Pedro De Pablos-Velasco. (2010) Grado de control metabólico en una población diabética atendida en servicios de endocrinología. Endocrinología y Nutrición 57:10, pages 472-478.
Crossref
Crossref
G. E. Peterson & R. D. Pollom. (2010) Liraglutide in clinical practice: dosing, safety and efficacy. International Journal of Clinical Practice 64, pages 35-43.
Crossref
Crossref
N. Danchin, É. Eschwège, S. Bekka & M. Krempf. (2010) Variations pondérales, risque cardiométabolique et impact des médicaments antidiabétiques chez le diabétique de type 2. Annales de Cardiologie et d'Angéiologie 59:4, pages 214-220.
Crossref
Crossref
B. W. Bode, M. A. Testa, M. Magwire, P. M. Hale, M. Hammer, L. Blonde & A. Garber. (2010) Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:7, pages 604-612.
Crossref
Crossref
Hisham A. Alrefai, Kashif A. Latif, Laura B. Hieronymus, Cindy R. Weakley & Robert J. Moss. (2010) Pramlintide: Clinical Strategies for Success. Diabetes Spectrum 23:2, pages 124-130.
Crossref
Crossref